Antiviral treatment of HCV-related chronic hepatitis: is the cup half empty, or half full?
Puoti
Claudio
C
D000998:Antiviral Agents / Q000008:administration & dosage*; D029681:Arabidopsis Proteins; D036022:Capsid Proteins; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins
D000998:Antiviral Agents; D029681:Arabidopsis Proteins; C512167:BDG protein, Arabidopsis; D036022:Capsid Proteins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C442539:VP0 protein, Poliovirus; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a